Literature DB >> 16487050

Proteasome regulation of oxidative stress in aging and age-related diseases of the CNS.

Qunxing Ding1, Edgardo Dimayuga, Jeffrey N Keller.   

Abstract

Proteasome-mediated protein degradation is responsible for a large percentage of bulk protein turnover, particularly the degradation of short-lived and oxidized proteins. Increasing evidence suggests that proteasome inhibition occurs during the aging of the central nervous system (CNS), and in a variety of age-related disorders of the CNS. The focus of this review is to discuss the role of the proteasome as a regulator of oxidative stress, with preservation of proteasome function playing an important role in preventing oxidative stress, and proteasome inhibition playing an important role as a mediator of oxidative stress. In particular, this review will describe experimental evidence that proteasome inhibition is sufficient to induce mitochondrial dysfunction, increase reactive oxygen species generation, elevate RNA and DNA oxidation, and promote protein oxidation. Taken together, these data indicate that the proteasome is an important regulator of oxidative damage in the CNS, and suggest that proteasome inhibition may serve as an important switch for the induction of oxidative stress in the CNS. Additionally we discuss the likelihood that the 20S proteasome and 26S proteasome may play different roles in regulating oxidative stress and neurotoxicity in the aging CNS, and in age-related disorders of the CNS.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16487050     DOI: 10.1089/ars.2006.8.163

Source DB:  PubMed          Journal:  Antioxid Redox Signal        ISSN: 1523-0864            Impact factor:   8.401


  52 in total

1.  The switch-like expression of heme-regulated kinase 1 mediates neuronal proteostasis following proteasome inhibition.

Authors:  Beatriz Alvarez-Castelao; Susanne Tom Dieck; Claudia M Fusco; Paul Donlin-Asp; Julio D Perez; Erin M Schuman
Journal:  Elife       Date:  2020-04-24       Impact factor: 8.140

2.  Proteasome inhibitor MG-132 induces C6 glioma cell apoptosis via oxidative stress.

Authors:  Wen-hai Fan; Yi Hou; Fan-kai Meng; Xiao-fei Wang; Yi-nan Luo; Peng-fei Ge
Journal:  Acta Pharmacol Sin       Date:  2011-04-18       Impact factor: 6.150

3.  Effects of aging and dietary restriction on ubiquitination, sumoylation, and the proteasome in the spleen.

Authors:  Le Zhang; Feng Li; Edgardo Dimayuga; Jeffrey Craddock; Jeffrey N Keller
Journal:  FEBS Lett       Date:  2007-11-06       Impact factor: 4.124

4.  Proteasome modulates mitochondrial function during cellular senescence.

Authors:  Claudio A Torres; Viviana I Perez
Journal:  Free Radic Biol Med       Date:  2007-10-10       Impact factor: 7.376

5.  Differential activities of the ubiquitin-proteasome system in neurons versus glia may account for the preferential accumulation of misfolded proteins in neurons.

Authors:  Suzanne Tydlacka; Chuan-En Wang; Xuejun Wang; Shihua Li; Xiao-Jiang Li
Journal:  J Neurosci       Date:  2008-12-03       Impact factor: 6.167

6.  Aging and dietary restriction effects on ubiquitination, sumoylation, and the proteasome in the heart.

Authors:  Feng Li; Le Zhang; Jeffrey Craddock; Annadora J Bruce-Keller; Kalavathi Dasuri; AnhThao Nguyen; Jeffrey N Keller
Journal:  Mech Ageing Dev       Date:  2008-04-30       Impact factor: 5.432

7.  The proteasome: a target of oxidative damage in cultured human retina pigment epithelial cells.

Authors:  Xinyu Zhang; Jilin Zhou; Alexandre F Fernandes; Janet R Sparrow; Paulo Pereira; Allen Taylor; Fu Shang
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-04-11       Impact factor: 4.799

8.  Curcumin and its derivatives: their application in neuropharmacology and neuroscience in the 21st century.

Authors:  Wing-Hin Lee; Ching-Yee Loo; Mary Bebawy; Frederick Luk; Rebecca S Mason; Ramin Rohanizadeh
Journal:  Curr Neuropharmacol       Date:  2013-07       Impact factor: 7.363

9.  Tau protein degradation is catalyzed by the ATP/ubiquitin-independent 20S proteasome under normal cell conditions.

Authors:  Tilman Grune; Diana Botzen; Martina Engels; Peter Voss; Barbara Kaiser; Tobias Jung; Stefanie Grimm; Gennady Ermak; Kelvin J A Davies
Journal:  Arch Biochem Biophys       Date:  2010-05-15       Impact factor: 4.013

Review 10.  Hypoxia inducible factor 1 as a therapeutic target in ischemic stroke.

Authors:  Honglian Shi
Journal:  Curr Med Chem       Date:  2009       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.